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Objectives
Clinical trials often generate large and diverse datasets.
Data models are used to capture and organise the ele-
ments of the data in a meaningful way so that they can
be stored and utilised by computer systems and support
clinical decision making. This paper presents the data
modeling considerations within the ‘Clinical Trial Meth-
ods in Neurodegenerative Diseases’ (CTMND) project
funded by the NIHR [http://www.ctmnd.org].
The project adopts a holistic approach for the investi-
gation of the suitability and efficiency of clinical obser-
vations in neurodegenerative diseases clinical studies.
This ongoing research in novel clinical and surrogate
outcome measures will be incorporated in an online
data collection and analysis system to facilitate clinical
trials and relevant research, taking into account, wher-
ever possible, routinely collected NHS data.
This paper presents ongoing research in the project’s
data modeling aspects with the following objectives:
1. To review the current state of the art data models
for capturing clinical information from the available
literature.
2. To compare and contrast their features against the
data management requirements of the project and out-
line the key factors that affected the adoption of a speci-
fic model for the CTMND project’s information system.
Methods
A set of key papers and past reviews were collected
from the currently available literature detailing the char-
acteristics of standard data models used in healthcare
such as CDISC’s ODM, Health Level 7 and others. The
data models and associated approaches were compared
and contrasted with each other by taking into account
best practices and guidelines emerging from organiza-
t i o n ss u c ha st h eO b j e c tM a n a g e m e n tG r o u p( O M G ) .
Finally, having concluded in a specific modeling
approach we were also able to look forward at the possi-
bilities that a particular solution enables and propose a
flexible way to model clinical trial data.
Results
This review highlights a number of key data manage-
ment and organization considerations that affect the
adoption of a specific data model given the project spe-
cifications and resource constraints. The key factors
were Current Resources, Interoperability (with current
and future systems), Documentation and Reference
Implementation availability.
Conclusions
Given the dynamic environment of clinical trials as well
as the project’s objectives to propose novel outcome
measures, we comment on the suitability of the Dual
Model approach for the efficient organization of clinical
study data but more importantly for its flexibility in
modeling novel outcomes with minimal software main-
tenance. According to this approach, a handful of ele-
mentary data structures (numbers, character sequences,
lists, trees and others) are made available to a higher
level model that is responsible for their ordering and
semantics. Additionally we provide specific details
regarding system implementation.
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